However, S100A5 knockdown plus anti‐PD‐1 treatment showed the highest efficacy in inhibiting tumor burden, indicating that S100A5 downregulation could enhance the efficacy of anti‐PD‐1 treatment. Here, PDCD1 is linked to neoplasm.